This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Successfully Accessing Medical Equipment Markets In CIVETS

NEW YORK, March 28, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Successfully Accessing Medical Equipment Markets in CIVETS http://www.reportlinker.com/p01048236/Successfully-Accessing-Medical-Equipment-Markets-in-CIVETS.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply

Analysis of the health environment and commercial prospects in 6 high-growth emerging markets

For the last few years much interest and effort has been invested to better understand the first tier emerging markets of Brazil, Russia, India and China. But as that understanding matures, the spotlight is increasingly being cast on tier two markets that combine large populations with low median age, significant unmet clinical need, and rising economic performance. These markets have become known collectively since 2009 by the acronym CIVETS.

The CIVETS markets are geographically diverse but in common offer medical device and equipment manufacturers strong reliance on imports and rapid growth rates. At a time when established first-world markets are experiencing growth of 0-3% and with long-term issues around reducing sovereign debt, CIVETS such as Turkey and Indonesia are offering medical market growth rates of 7.4% and 14.5% respectively in the medium-term, albeit from a lower value base.Of course, the political and health infrastructure in many of these markets is less stable and developed, and that is why this new report from Espicom is the perfect detailed briefing of significant long-term opportunities in these countries.

Understand fully the prospects and operating environment in these key emerging markets with this excellent report service

Driven by patient populationAll markets, including health, are per capita driven. But simple per capita considerations are not sufficient to appreciate the changing health profile of a country and the demand for health services/infrastructure. Understanding these dynamics will identify the potential for suppliers of medical devices, equipment and supplies and their related supportservices.

A key aspect which links CIVETS is a growing population that is young, technologically sophisticated and consumer orientated. The median age in the 6 CIVETS markets is 27; in Egypt it is just 24. By comparison, the median ages in the US and UK are 37 and 40, respectively. This profile of large numbers of economically active individuals, along with development of diverse economic activity, often related to mineral wealth, is driving GDP up and hence the improvement in social and health provision.

65+ population group to rise slowlyAt the same time, for the medium term, the number of elderly (65+) as a % of the population will rise relatively slowly – this group places the largest demand on health services and hence its impact on health spending is significant. Compare the following stats for an example:

% of population aged over 65 by 2016 Indonesia 6.6% France 19%

While varying widely within the CIVETS group, it is fair to say that the infrastructure and provision of health services in all CIVETS has some way to go before reaching first-world standards. Beyond mostly city based hi-tech health facilities lies much unmet clinical need in poorly provided rural areas, with only the most basic support services available. A further issue to consider is the role played by aid in the development of health services.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,065.78 +86.65 0.51%
S&P 500 1,993.30 +6.79 0.34%
NASDAQ 4,531.4180 +4.9360 0.11%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs